IPP Bureau
RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr
By IPP Bureau - October 22, 2025
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC
By IPP Bureau - October 22, 2025
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer
By IPP Bureau - October 22, 2025
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders
By IPP Bureau - October 22, 2025
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Roche presents positive phase III data for vamikibart in uveitic macular edema
By IPP Bureau - October 22, 2025
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
AbbVie's Rinvoq beats Humira in key arthritis trial
By IPP Bureau - October 22, 2025
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Cambrex to invest $120 million to expand API manufacturing in US
By IPP Bureau - October 22, 2025
Expanding US operations to address the increased demand for API development and manufacturing
FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
By IPP Bureau - October 21, 2025
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Roquette opens health and pharma solutions innovation center in Brazil
By IPP Bureau - October 20, 2025
This new facility strengthens Latin America as a collaborative hub
FDA approves Alembic’s Triamcinolone Acetonide injectable suspension USP, 40 mg/mL
By IPP Bureau - October 19, 2025
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Cupid achieves CE (EU IVDR) certification for pregnancy and syphilis test kits
By IPP Bureau - October 19, 2025
Gujarat Themis Biosyn doubles fermentation production capacity at Vapi
By IPP Bureau - October 19, 2025
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
Strides partners with Incepta to expand women's health access with WHO-prequalified contraceptive
By IPP Bureau - October 18, 2025
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Indegene strengthens consulting practice to accelerate life sciences transformation
By IPP Bureau - October 18, 2025
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
IKS Health announces generative AI platform built on Google cloud
By IPP Bureau - October 18, 2025
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
